person · Reporting owner

KLEIN JOSEPH III

Disclosed activity across 2 companies

Tapewire entity: 32405
SEC CIK: 0001206369

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IONIS PHARMACEUTICALS INCIONS · Entity 1182	Director	July 01, 2026	July 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IONIS PHARMACEUTICALS INC

Report date July 01, 2026 · Filed July 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,014	Ending reported balance After 2026-07-01 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-07-01 · Exercise / conversion · Acquired 11,518 · Balance 22,532 Row 2 · 2026-07-01 · Sale · Disposed 99 · Balance 22,433 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. Row 3 · 2026-07-01 · Sale · Disposed 11,419 · Balance 11,014 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.94 · Expires 2035-06-30	Direct	0	Reported balance After 2026-07-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-07-01 · Exercise / conversion · Disposed 11,518 · Balance 0
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.19 · Expires 2036-06-30	Direct	5,369	Reported balance After 2026-07-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-07-01 · Grant · Acquired 5,369 · Balance 5,369 F4: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F5: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	16,277	Reported balance After 2026-07-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-07-01 · Grant · Acquired 2,301 · Balance 16,277 F6: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F7: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026.
Common StockSEC Table I · non-derivative	Indirectby Son	200	Reported balance Holding disclosure · report date 2026-07-01 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 200 F3: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

F3: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F4: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F5: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.

F6: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AKCEA THERAPEUTICS, INC.

Report date October 12, 2020 · Filed October 13, 2020

Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-04-12	Direct	0	Reported balance After 2020-10-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-10-12 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: This option, which provided for vesting of the shares on the 12-month anniversary of the date of grant, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.

Filing footnotes · ownership attribution and instrument terms

F1: This option, which provided for vesting of the shares on the 12-month anniversary of the date of grant, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 01, 2026 Filed Jul 6, 2026 22:49 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	2,301	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-26-000229 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,277 Underlying: Common Stock · 2,301 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F7 · derivative.exercise_date: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026. F7 · derivative.expiration_date: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026. Read SEC document
July 01, 2026 Filed Jul 6, 2026 22:49 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	5,369	$0.00 Strike: $79.19	$0.00	Disclosure SEC source: 0000874015-26-000229 · edgardoc.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires 2036-06-30 F4 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F5 · derivative.exercise_date: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. F5 · derivative.expiration_date: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. Read SEC document
July 01, 2026 Filed Jul 6, 2026 22:49 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	11,518	$0.00 Strike: $39.94	$0.00	Disclosure SEC source: 0000874015-26-000229 · edgardoc.xml · derivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,518 shares Expires 2035-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 01, 2026 Filed Jul 6, 2026 22:49 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	11,419	$79.04	$902,550.91	Disclosure SEC source: 0000874015-26-000229 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,014 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
July 01, 2026 Filed Jul 6, 2026 22:49 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	99	$79.45	$7,865.55	Disclosure SEC source: 0000874015-26-000229 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,433 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. Read SEC document
July 01, 2026 Filed Jul 6, 2026 22:49 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	11,518	$39.94	$460,028.92	Disclosure SEC source: 0000874015-26-000229 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2026 Filed May 5, 2026 20:30 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	10,111	$0.00 Strike: $47.11	$0.00	Disclosure SEC source: 0000874015-26-000182 · edgardoc.xml · derivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,111 shares Expires 2034-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2026 Filed May 5, 2026 20:30 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	1,431	$74.45	$106,534.23	Disclosure SEC source: 0000874015-26-000182 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,014 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.07 to $74.92 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document
May 01, 2026 Filed May 5, 2026 20:30 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	8,680	$73.35	$636,704.04	Disclosure SEC source: 0000874015-26-000182 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,445 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.95 to $73.64 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
May 01, 2026 Filed May 5, 2026 20:30 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	10,111	$47.11	$476,329.21	Disclosure SEC source: 0000874015-26-000182 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2026 Filed Apr 2, 2026 23:43 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	10,321	$0.00 Strike: $41.08	$0.00	Disclosure SEC source: 0000874015-26-000161 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,321 shares Expires 2033-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2026 Filed Apr 2, 2026 23:43 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $38.06	$0.00	Disclosure SEC source: 0000874015-26-000161 · edgardoc.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2026 Filed Apr 2, 2026 23:43 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	2,216	$75.95	$168,314.06	Disclosure SEC source: 0000874015-26-000161 · edgardoc.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,014 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.88 to $76.17 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document
April 01, 2026 Filed Apr 2, 2026 23:43 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	20,105	$75.50	$1,517,987.82	Disclosure SEC source: 0000874015-26-000161 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,230 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.865 to $75.85 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
April 01, 2026 Filed Apr 2, 2026 23:43 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	10,321	$41.08	$423,986.68	Disclosure SEC source: 0000874015-26-000161 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 01, 2026 Filed Apr 2, 2026 23:43 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	12,000	$38.06	$456,720.00	Disclosure SEC source: 0000874015-26-000161 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 03, 2026 Filed Mar 5, 2026 23:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,000	$0.00 Strike: $42.88	$0.00	Disclosure SEC source: 0000874015-26-000137 · edgardoc.xml · derivative · entry 8 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 03, 2026 Filed Mar 5, 2026 23:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $40.05	$0.00	Disclosure SEC source: 0000874015-26-000137 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2031-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 03, 2026 Filed Mar 5, 2026 23:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	1,012	$80.82	$81,787.82	Disclosure SEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,014 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.67 to $81.025 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document
March 03, 2026 Filed Mar 5, 2026 23:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	6,794	$80.00	$543,486.03	Disclosure SEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,026 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.65 to $80.63 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document
March 03, 2026 Filed Mar 5, 2026 23:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	13,526	$79.17	$1,070,907.52	Disclosure SEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,820 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.615 to $79.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
March 03, 2026 Filed Mar 5, 2026 23:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	4,000	$42.88	$171,520.00	Disclosure SEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 03, 2026 Filed Mar 5, 2026 23:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	12,000	$40.05	$480,600.00	Disclosure SEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,000	$0.00 Strike: $60.20	$0.00	Disclosure SEC source: 0000874015-25-000286 · edgardoc.xml · derivative · entry 11 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,000	$0.00 Strike: $60.20	$0.00	Disclosure SEC source: 0000874015-25-000286 · edgardoc.xml · derivative · entry 10 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,000	$0.00 Strike: $60.20	$0.00	Disclosure SEC source: 0000874015-25-000286 · edgardoc.xml · derivative · entry 9 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 8,000 Underlying: Common Stock · 4,000 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	4,000	$80.00	$320,000.00	Disclosure SEC source: 0000874015-25-000286 · edgardoc.xml · nonDerivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024 F2 · ownership.nature: The reporting person disclaims beneficial ownership of all securities held in the children's trusts, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0000874015-25-000286 · edgardoc.xml · nonDerivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	4,000	$80.00	$320,000.00	Disclosure SEC source: 0000874015-25-000286 · edgardoc.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024 F2 · ownership.nature: The reporting person disclaims beneficial ownership of all securities held in the children's trusts, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0000874015-25-000286 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	4,000	$80.00	$320,000.00	Disclosure SEC source: 0000874015-25-000286 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024 F2 · ownership.nature: The reporting person disclaims beneficial ownership of all securities held in the children's trusts, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0000874015-25-000286 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:37 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	16,000	$0.00 Strike: $52.22	$0.00	Disclosure SEC source: 0000874015-25-000219 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2027-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:37 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $42.88	$0.00	Disclosure SEC source: 0000874015-25-000219 · edgardoc.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:37 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	28,000	$60.00	$1,680,000.00	Disclosure SEC source: 0000874015-25-000219 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024 Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:37 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	12,000	$0.00	$0.00	Disclosure SEC source: 0000874015-25-000219 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 28,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:37 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	16,000	$0.00	$0.00	Disclosure SEC source: 0000874015-25-000219 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:38 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	16,000	$0.00 Strike: $52.22	$0.00	Disclosure SEC source: 0000874015-25-000220 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2027-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:38 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $42.88	$0.00	Disclosure SEC source: 0000874015-25-000220 · edgardoc.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:38 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	28,000	$60.00	$1,680,000.00	Disclosure SEC source: 0000874015-25-000220 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024 Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:38 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	12,000	$0.00	$0.00	Disclosure SEC source: 0000874015-25-000220 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 28,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2025 Filed Sep 5, 2025 00:38 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	16,000	$0.00	$0.00	Disclosure SEC source: 0000874015-25-000220 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 01, 2025 Filed Jul 2, 2025 20:53 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	5,220	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-25-000140 · edgardoc.xml · derivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,976 Underlying: Common Stock · 5,220 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025. F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025. Read SEC document
July 01, 2025 Filed Jul 2, 2025 20:53 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	11,518	$0.00 Strike: $39.94	$0.00	Disclosure SEC source: 0000874015-25-000140 · edgardoc.xml · derivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,518 Underlying: Common Stock · 11,518 shares Expires 2035-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025. F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025. Read SEC document
July 16, 2024 Filed Jul 17, 2024 21:02 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $24.42	$0.00	Disclosure SEC source: 0000874015-24-000180 · edgardoc.xml · derivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 16, 2024 Filed Jul 17, 2024 21:02 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	12,000	$50.00	$600,000.00	Disclosure SEC source: 0000874015-24-000180 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024 Read SEC document
July 16, 2024 Filed Jul 17, 2024 21:02 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	12,000	$24.42	$293,040.00	Disclosure SEC source: 0000874015-24-000180 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 01, 2024 Filed Jul 3, 2024 18:47 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	4,079	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-24-000163 · edgardoc.xml · derivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,756 Underlying: Common Stock · 4,079 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant of Restricted Stock Unit award on July 1, 2024 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2024 F4 · derivative.expiration_date: Grant of Restricted Stock Unit award on July 1, 2024 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2024 Read SEC document
July 01, 2024 Filed Jul 3, 2024 18:47 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,111	$0.00 Strike: $47.11	$0.00	Disclosure SEC source: 0000874015-24-000163 · edgardoc.xml · derivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,111 Underlying: Common Stock · 10,111 shares Expires 2034-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024. F2 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024. Read SEC document
May 03, 2024 Filed May 7, 2024 20:55 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	930	$42.90	$39,893.00	Disclosure SEC source: 0000874015-24-000144 · edgardoc.xml · nonDerivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.80 to $43.54 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.